Saturday, August 11, 2012
Dr. Reddy's - secular growth story
Read, understand and consent to the blog's DISCLAIMER here before proceeding to read the article
June 2012 IR Presentation -> Link
1. North America Generics - Increased number of launches for the next 2-3 years. Limited competition products growing (Revenue at $200m)
2. Russia - Growing very strong. Increasing OTC and new biosimilar opportunity
3. GSK partnership - growth in other emerging markets
4. Longer term - Merck-Sereno partnership for biosimilars in regulated markets
Note->If you like to receive updates in future on stocks directly to your email inbox, you may want to consider subscribing to the blog's posts for free. Just enter your email id in the text box under the big red arrow to the right.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment